Bionic ear maker Cochlear recalls hearing implants

September 13, 2011

(AP) -- Bionic ear maker Cochlear has been forced to begin a global recall of the world's thinnest hearing implants after some stopped working.

The Sydney-based company, which dominates the world's bionic ear market, said Monday it was mystified as to why some of its award-winning Nucleus CI500 devices were suddenly shutting down.

The company has begun recalling its entire Nucleus CI500 range, which makes up the bulk of its sales, from shelves after a rise in the number of faults with the CI512 model.

While believes the faults are unlikely to cause any for people with defective implants, they are offering replacement models for re-implantation.

The news sent Cochlear's shares into a tailspin, with the stock dropping more than 25 percent at one stage amid worries about the and potential damage to the company's reputation the recall could cause.

Shares in Cochlear fell 14.68 Australian dollars ($15.21), or 20 percent, to close Monday at AU$57.50 ($59.58), the lowest in over two years.

Cochlear chief executive Chris Roberts said he was unable to say how many of the "very reliable" titanium-based devices were faulty.

While less than 1 percent of the Nucleus CI500 devices had failed since they hit the market in 2009, there had been a steady rise in faults being reported in recent weeks.

"We don't know what the cause is," Roberts told analysts on a conference call.

"That's exactly what we need to evaluate. We want to avoid saying it's 'a' or 'b' or 'c' when we have to up every stone and examine every possibility," he added.

People fitted with CI500 units but who have not experienced any problems are being advised to continue using the devices.

The voluntary recall of the Nucleus CI500 range includes the CI512 model as well as the CI513, CI551 double array implant and ABI 541 auditory brainstem implant.

It does not affect its earlier Nucleus Freedom range or its Nucleus 5 external hearing devices.

Production of the CI500 devices has stopped and patients needing bionic ear implants are being offered the Nucleus Freedom model, which has been on the market for seven years.

Roberts said Cochlear was better off halting manufacture until the cause of the faults was uncovered.

He was unable to say how long it would take before the devices were back on sale but said if any changes had to be made, the company would need to get regulatory approval from the countries where the units are sold.

Cochlear was also unable to say what the cost of the product recall would be.

Cochlear sold more than 17,000 of its Nucleus 5 range of devices in the 2010/11 financial year, representing 70 percent of its total bionic ear sales in 100 different countries.

The Nucleus 5 range includes the thinnest hearing implants on the market at just 3.9 millimeters (0.15 of an inch) thick.

Cochlear has promoted them as "a new design that is built to last a lifetime."

shares

Related Stories

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.